Cargando…

Natural products as LSD1 inhibitors for cancer therapy

Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new er...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yuan, Yang, Chao, Yu, Zhiqiang, Li, Xiaochuan, Mu, Qingchun, Liao, Guochao, Yu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305746/
https://www.ncbi.nlm.nih.gov/pubmed/32837872
http://dx.doi.org/10.1016/j.apsb.2020.06.007
_version_ 1783548528963878912
author Fang, Yuan
Yang, Chao
Yu, Zhiqiang
Li, Xiaochuan
Mu, Qingchun
Liao, Guochao
Yu, Bin
author_facet Fang, Yuan
Yang, Chao
Yu, Zhiqiang
Li, Xiaochuan
Mu, Qingchun
Liao, Guochao
Yu, Bin
author_sort Fang, Yuan
collection PubMed
description Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new era. Natural products have also shown promise in epigenetic drug discovery, some of them have advanced into clinical trials or are presently being used in clinic. The histone lysine specific demethylase 1 (LSD1), an important class of histone demethylases, has fundamental roles in the development of various pathological conditions. Targeting LSD1 has been recognized as a promising therapeutic option for cancer treatment. Notably, some natural products with different chemotypes including protoberberine alkaloids, flavones, polyphenols, and cyclic peptides have shown effectiveness against LSD1. These natural products provide novel scaffolds for developing new LSD1 inhibitors. In this review, we mainly discuss the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity and their modes of action. We also briefly discuss the challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors.
format Online
Article
Text
id pubmed-7305746
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73057462020-06-22 Natural products as LSD1 inhibitors for cancer therapy Fang, Yuan Yang, Chao Yu, Zhiqiang Li, Xiaochuan Mu, Qingchun Liao, Guochao Yu, Bin Acta Pharm Sin B Review Natural products generally fall into the biologically relevant chemical space and always possess novel biological activities, thus making them a rich source of lead compounds for new drug discovery. With the recent technological advances, natural product-based drug discovery is now reaching a new era. Natural products have also shown promise in epigenetic drug discovery, some of them have advanced into clinical trials or are presently being used in clinic. The histone lysine specific demethylase 1 (LSD1), an important class of histone demethylases, has fundamental roles in the development of various pathological conditions. Targeting LSD1 has been recognized as a promising therapeutic option for cancer treatment. Notably, some natural products with different chemotypes including protoberberine alkaloids, flavones, polyphenols, and cyclic peptides have shown effectiveness against LSD1. These natural products provide novel scaffolds for developing new LSD1 inhibitors. In this review, we mainly discuss the identification of natural LSD1 inhibitors, analysis of the co-crystal structures of LSD1/natural product complex, antitumor activity and their modes of action. We also briefly discuss the challenges faced in this field. We believe this review will provide a landscape of natural LSD1 inhibitors. Elsevier 2021-03 2020-06-20 /pmc/articles/PMC7305746/ /pubmed/32837872 http://dx.doi.org/10.1016/j.apsb.2020.06.007 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Fang, Yuan
Yang, Chao
Yu, Zhiqiang
Li, Xiaochuan
Mu, Qingchun
Liao, Guochao
Yu, Bin
Natural products as LSD1 inhibitors for cancer therapy
title Natural products as LSD1 inhibitors for cancer therapy
title_full Natural products as LSD1 inhibitors for cancer therapy
title_fullStr Natural products as LSD1 inhibitors for cancer therapy
title_full_unstemmed Natural products as LSD1 inhibitors for cancer therapy
title_short Natural products as LSD1 inhibitors for cancer therapy
title_sort natural products as lsd1 inhibitors for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305746/
https://www.ncbi.nlm.nih.gov/pubmed/32837872
http://dx.doi.org/10.1016/j.apsb.2020.06.007
work_keys_str_mv AT fangyuan naturalproductsaslsd1inhibitorsforcancertherapy
AT yangchao naturalproductsaslsd1inhibitorsforcancertherapy
AT yuzhiqiang naturalproductsaslsd1inhibitorsforcancertherapy
AT lixiaochuan naturalproductsaslsd1inhibitorsforcancertherapy
AT muqingchun naturalproductsaslsd1inhibitorsforcancertherapy
AT liaoguochao naturalproductsaslsd1inhibitorsforcancertherapy
AT yubin naturalproductsaslsd1inhibitorsforcancertherapy